LBP-22 - Twelve-week treatment with BOS-580, a novel, long-acting Fc-FGF-21 fusion protein, leads to a reduction in liver steatosis, liver injury, and fibrosis in patients with phenotypic NASH: a randomized, blinded, placebo-controlled phase 2A trial
| Autor: | Loomba, Rohit, Kowdley, Kris, Rodriguez, Jose, Kim, Nomita, Alvarez, Alina, Morrow, Linda, Yin, Philip, Amaravadi, Lakshmi, Jeglinski, Brenda, Clawson, Alicia, Chowdhury, Swapan, Basson, Craig, Dumont, Etienne, Svensson, Eric, Odrljin, Tatjana |
|---|---|
| Zdroj: | In Journal of Hepatology June 2023 78 Supplement 1:S115-S116 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect